PHARMACOGENETICS OF PRO 12ALA PPAR-GAMMA-2

PRO 12ALA PPAR-GAMMA-2 的药物遗传学

• 批准号: 7376930
• 负责人: ALAN R. SHULDINER
• 金额: $ 0.59万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376930
• 关键词: PHARMACOGENETICS; PRO; 12ALA; PPAR; GAMMA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this protocol is to determine why some individuals do not respond well to thiazolidinediones, a class of antidiabetic drugs. These drugs work by improving the sensitivity of the body to insulin. Subjects will be recruited on the basis of their genotype, as it is believed that a particular variant (Pro 12Ala PPAR-gamma-2) may cause a blunted response to these drugs. Subjects with impaired glucose tolerance (a precursor of diabetes) will be recruited and treated with rosiglitazone, a thiazolidinedione. Insulin sensitivity will be tested before and after a 12 week treatment with rosiglitazone, both in terms of glucose uptake an inhibition of lipolysis (fat breakdown). Likewise, gene expression in fat and muscle will be studies before and after treatment. The protocol concludes with a 12 week didactic weight management program.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该方案的目的是确定为什么一些人对噻唑烷二酮类抗糖尿病药物反应不佳。这些药物通过提高人体对胰岛素的敏感度来发挥作用。受试者将根据他们的基因被招募，因为人们认为一个特定的变种(Pro 12Ala PPAR-Gamma-2)可能会导致对这些药物的迟钝反应。糖耐量受损(糖尿病的先兆)的受试者将被招募并接受罗格列酮治疗，罗格列酮是一种噻唑烷二酮。胰岛素敏感性将在罗格列酮治疗12周之前和之后进行测试，包括葡萄糖摄取和抑制脂肪分解(脂肪分解)。同样，脂肪和肌肉中的基因表达将在治疗前后进行研究。该方案以12周的说教体重管理计划结束。